AstraZeneca: Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients With Metastatic HR-Positive, HER2-Low or Negative Breast Cancer in TROPION-Breast01 Phase III Trial
September 23, 2024
September 23, 2024
WILMINGTON, Delaware, Sept. 23 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Survival results for AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in TROPION-Breast01 did not achieve statistical significance versus chemotherapy
Trial previously met the dual primary endpoint of progression-free survival
* * *
High-level results from the TROPION-Breast01 Phase III trial of datop . . .
* * *
Survival results for AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in TROPION-Breast01 did not achieve statistical significance versus chemotherapy
Trial previously met the dual primary endpoint of progression-free survival
* * *
High-level results from the TROPION-Breast01 Phase III trial of datop . . .